Mariner
COGT icon

Mariner’s Cogent Biosciences COGT Stock Holding History

Mariner’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$313K Buy
+8,097
New +$283K ﹤0.01% 2811
2026
Q1 		– Sell
-7,148
Closed -$252K – 3612
2025
Q4 		$252K Buy
+7,148
New +$201K ﹤0.01% 2991

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Mariner's COGT Position: Q2 2026 in Review

Mariner opened a new position in Cogent Biosciences (COGT) in Q2 2026: 8,097 shares worth $313K. The stake represents ﹤0.01% of the portfolio and ranks #2811 among its holdings. This is a return to the name: Mariner previously reported a position in COGT as recently as Q4 2025.

Mariner first reported a position in COGT in Q4 2025 and has held it in 2 quarters since. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Mariner held 8,097 shares of Cogent Biosciences worth $313K as of Q2 2026.
  • Cogent Biosciences was a new Mariner position in Q2 2026.
  • Cogent Biosciences made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2811 holding.
  • Mariner first reported a position in Cogent Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.